Pacira BioSciences, Inc.
PCRX
Positions held
Your positionsPCRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Pacira BioSciences is strategically positioned in the specialty pharmaceuticals sector, focusing on innovative pain management solutions that address significant unmet medical needs.
- In Q2 2026, Pacira reported a revenue increase of 8% compared to the previous quarter, reaching $192 million.
- The operating margin expanded to 6.2% in the same quarter, indicating improved operational efficiency.
- Despite recent revenue growth, the company has a trailing P/E ratio of 70.74, suggesting it may be overvalued relative to its earnings.
- In Q1 2026, the operating margin was only 2.6%, highlighting ongoing profitability challenges.
- Pacira's net income for 2025 was just $7.034 million, reflecting a struggle to maintain consistent profitability.
Fundamentals
| Market cap | $1.45B | Enterprise value | $1.61B | Trailing P/E | 103.76 | Forward P/E | 10.50 |
| PEG | 0.68 | Price / book | 2.15 | Beta | 0.25 | Dividend yield | 0.00% |
| Revenue growth | 6.2% | Earnings growth | — | Gross margin | 79.2% | Operating margin | 6.2% |
| Profit margin | 2.0% | ROE | 2.0% | ROA | 1.5% | Debt / equity | 0.61 |
| Current ratio | 5.04 | Free cash flow | $98.34M | Analyst recommendation | buy | Mean target | $31.39 |
| 52w high | $36.46 | 52w low | $18.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $192M | $177M | $197M | $180M | $181M | — |
| Op margin | 6.2% | 2.6% | -5.5% | 7.3% | 5.0% | — |
| Net income | $4.7M | $2.9M | $1.6M | $5.4M | -$4.8M | — |
| Gross margin | 77.0% | 79.5% | 79.5% | 80.9% | 77.4% | — |
| Gross profit | $148M | $141M | $157M | $145M | $140M | — |
| Operating income | $11.9M | $4.6M | -$10.9M | $13.2M | $9.1M | — |
- Revenue +8% vs prior quarter ($192M vs $177M).
- Gross margin 77% (was 79.5% prior quarter).
- Operating margin expanded to 6.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $726M | $701M | $675M | $667M |
| Op margin | 2.6% | 12.8% | 13.0% | 9.0% |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M |
| Gross margin | 79.4% | 75.7% | 72.6% | 70.1% |
| Gross profit | $577M | $531M | $490M | $468M |
| Operating income | $19.2M | $89.9M | $87.7M | $60.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · HC Wainwright Downgrades Pacira Biosciences to Neutral, Price Target is $36.50
2026-10-09 · Oppenheimer Downgrades Pacira Biosciences to Perform From Outperform on Heels of Announced Sale to Viatris
2026-10-09 · Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
2026-10-08 · Stocks to Watch Recap: Intel, Samsung, PepsiCo, TSMC
2026-10-08 · Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
2026-10-08 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-10-08 · Viatris to acquire Pacira BioSciences for $1.65 billion
2026-10-08 · Top Midday Gainers
2026-10-08 · Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?
2026-10-08 · HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
2026-10-08 · Sector Update: Healthcare Stocks Decline in Afternoon Trading
2026-10-08 · Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
Price (daily)
Full chart · RSI · MACD · patterns